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Abstract
BACKGROUND: The death rate for prostate cancer (PrCA), the most com-
monly diagnosed cancer in African-American (AA) men, is twice the rate of 
European-American (EA) men. AA men in South Carolina have the highest 
age-adjusted death rate in the nation. Studies have shown that treatment 
offered to AA men with PrCA is systematically different from that offered to 
EA men. METHODS: Surveys were mailed to 1,866 men in South Carolina with 
a diagnosis of PrCA. South Carolina men diagnosed with PrCA between 1996 
and 2002 were eligible to participate.  We performed a descriptive assess-
ment of the factors that influenced PrCA treatment decisions. RESULTS: The 
treatment choices of AA men were significantly more likely to be influenced 
by pain and significantly less likely to be influenced by potential for cure 
compared to EA men.  CONCLUSIONS:  Providers must be cognizant of the 
factors that influence treatment, particularly in AA men. Despite the national 
undertaking to eliminate health disparities, the United States is far from 
implementing a comprehensive focus on the health of AA men, despite their 
elevated PrCA morbidity and mortality rates.  
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Introduction
Studies have shown that treatment offered to African-American (AA) men 
with prostate cancer (PrCA) is systematically different from that offered to 
European-American (EA) men. At a comparable disease stage, AA men were 
less likely to receive aggressive treatment fpr PrCA compared to EA men.1-5 
More recent studies have found that AA men with PrCA are more likely than 
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Methods and Materials
PrCA cases from an eight-county area in the Midlands (area around 
Columbia) South Carolina were identified through the South Carolina Central 
Cancer Registry (SCCCR).  All men diagnosed between 1996 and 2002 were 
eligible to participate.  Due to the time lapse between 2002 and 2006, many 
men were deceased or had health conditions that prevented physicians from 
providing consent for the patient to be contacted.  A total of 1,866 patients 
were able to participate in the study.  A total of 541 responses were received, 
yielding a 29% response rate.  
The variables under investigation were framed by Holmboe et al.,11 
who developed a taxonomy that organized aspects of treatment into 
four Axes: External Information, Intrinsic Characteristics of Treatment, 
Personal Impressions, and Economic Concerns.  This taxonomy provides the 
groundwork for understanding patients’ preferences and how they connect 
to all aspects of decision-making and treatment satisfaction.  The variables 
collected from this survey include:  age when first screened for PrCA, number 
of  doctor visits, initial treatment and date, subsequent treatments and 
dates, person who most influenced treatment decision, clinical factors that 
influenced treatment decision, PSA level change, type of insurance, number 
of people in household, and accessibility to doctor visits.  
Descriptive analyses were performed using SAS (version 9.1).  
Responders were compared to non-responders in order to determine the 
representativeness of the study sample. Frequency distributions by race 
were used to evaluate the treatment and diagnostic variables across racial 
groups. Bivariate analyses were conducted using the t-test or chi-square 
test, as appropriate, to assess the associations between race/ethnicity and all 
variables, and differences between racial groups.  
EA men to receive conservative management or watchful waiting, after 
adjusting for stage, age, life expectancy, and co-morbidity. They are also more 
likely than EA men to receive no treatment for PrCA.1,4,6  
There are a variety of treatment options for patients with the same set 
of clinical factors; therefore, the implemented treatment must be influenced 
by non-clinical factors.  These other factors may contribute to the differences 
in observed treatments received by AA vs. EA PrCA patients.  The aim of 
this study is to describe and compare racial differences in social and clinical 
factors that may influence PrCA treatment decisions. In order to assess racial 
differences in factors that influence treatment decisions we utilized data from 
South Carolina, a state in which AA men have among the highest incidence 
and mortality rates in the country and world.7-9,10  
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Results
Comparison of responders to non-responders revealed significant 
differences (p<.0001) in both race and marital status between the groups, with 
the non-responder sample being approximately 48% EA (as opposed to 80% 
in the responder sample) and 75% of the men in this group (vs. 86% of the 
responders) being married.  Other characteristics of the non-responder sample 
were similar to those of responders, (e.g., having a mean ages of 66 and 71 
years, 81% of the men in both groups had localized disease, and 76% of non-
responders had moderately well-differentiated disease (vs. 71% of responders). 
Table I. shows the percentages for the variables used in this analysis by race/
ethnicity. The sample was 80% EA and 20% AA. Over 78% of the men were 
65 years and older and 85.8% were married. The majority of the sample had 
localized (81%) and moderately well-differentiated (72%) disease. AA men 
were more likely to be screened at an earlier age (58 vs 61.3 years), single, and 
living alone compared to EA men. PSA changes were significantly less likely 
to occur since last treatment in AA men (55%) than in their EA counterparts 
(66%).  
Some clinical factors differed significantly between the groups; however, 
no social factors were significant.  AA men were significantly (p<.05) less 
likely to report cure and significantly more likely to report pain as reason for 
treatment compared to EA men (Table II). The most commonly reported social 
influence was the doctor.  However, this reason did not vary significantly by 
race.
Discussion
We observed evidence of differences in clinical factors by race that may 
influence PrCA treatment decisions.  Compared to EA men, AA men were less 
likely to report that cure and more likely to report that pain influenced their 
treatment decision. Several plausible reasons could explain the differences 
between AA and EA men on factors associated with treatment decisions. 
Cancer  fatalism, the belief that death is inevitable when cancer is present, has 
been identified as a barrier to participation in cancer screening, detection, 
and treatment.12 Race also is associated with cancer fatalism.12-17 Powe found 
elderly African Americans had higher mean fatalism scores compared to 
elderly EAs.17  Fatalism and the belief that treating cancer was useless emerged 
as a major theme in a qualitative study of AAs by Greiner et al.18 Another 
reasonable explanation for lower percentages of AA men reporting cure as 
a reason for treatment might be their belief that God is the only one able 
to heal or cure cancer. The dependency on God to heal has been reported 
in several studies.19-22 Investigators at Emory University School of Medicine 
found some AAs believed that prayer and faith in God was the only cure for 
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(n = 431) 
Characteristics N (%) N (%) Χ2 (p-value)
Age (mean)** t-test 68 (sd-8) 72 (sd-8) -4.30 (<.0001)
Marital Status* 16.94 (.0002)
Unmarried (sep, divorce, 
widow) 24 (22) 35 (8)
Married 83 (75) 381 (88)
      Unknown 3 (3) 15 (3)
Treatment Type
Watchful Waiting 6 (5) 20 (5) .13 (.7216)
Surgery 58 (53) 224 (52) .02 (.8875)
Radiation 43 (39) 176 (41) .11 (.7394)
Hormone Therapy 10 (9) 59 (14) 1.67 (.1969)
Other (chemo, other) 3 (3) 7 (2) .59 (.4433)
Unknown* (including missing) 2 (2) 0 (0) 7.87 (.0050)
Treatment Aggressiveness† .9916 (.3193)
Aggressive 90 (86) 350 (82)
Conservative 15 (14) 79 (18)
Unknown (missing) 5 (5) 2 (.5)
Tumor grade 3.34 (.5025)
Well differentiated 5 (5) 37 (9)
Moderately differentiated 80 (73) 307 (71)
Poorly differentiated 17 (15) 65 (15)
Undifferentiated 1 (1) 1 (.2)
Not determined 7 (6) 21 (5)
Tumor stage 1.63 (.8035)
Localized 88 (80) 348 (81)
Regional 17 (15) 61 (14)
Distant Metastasized 1 (1) 2 (.5)
Unstaged 4 (4) 20 (5)
Lives with wife or partner* 9.06 (.0026)
Yes 84 (79) 379 (89)
No 23 (22) 45 (11)
Missing 3 (3) 7 (2)
Number of other people in the 
household* 18.21 (.0004)
0 18 (16) 49 (11)
1 62 (56) 327 (76)
> 1 24 (22) 45 (10)
     Missing 6 (5) 10 (2)
Difficulty attending doctor 
visits* 12.10 (.0005)
Yes 8 (7) 6 (1)
No 101 (93) 423 (99)
Missing 1 (1) 2 (.5)
* - Significant chi-square (p-value .05) † - Aggressive treatment includes surgery,                       
chemotherapy, and radiation treatment; conservative treatment includes hormone therapy 
and watchful waiting.
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(n = 432) 
Influences N (%) N (%) Χ2 (p-value)
Social ‡
Doctor 60 (55) 248 (57) .29 (.5885)
Family 27 (25) 93 (22) .46 (.4962)
Friend 4 (4) 10 (2) .61 (.4353)
Yourself 36 (33) 163 (38) .94 (.3310)
Other 1 (1) 6 (1) .16 (.6907)
Clinical 
Cure* 72 (65) 362 (84) 18.98 (<.0001)
Impotence 30 (27) 96 (22) 1.23 (.2682)
Incontinence 25 (23) 88 (20) .30 (.5948)
Pain* 13 (12) 15 (3) 12.41 (.0004)
Other 4 (4) 39 (9) 3.51 (.0610)
None* 14 (13) 18 (4) 11.51 (.0007)
* - Significant chi-square (p-value .05)
‡ - Some observations had multiple social influence choices.
There are some study limitations.  Though high in comparison to mail 
surveys, our response rate was only about one-third.   The accuracy of the 
reporting on treatment influences may have been compromised by recall-bias 
that, in turn, might be influenced by the presence of symptoms, including 
those resulting from treatment. However, we were most interested in the 
main social and clinical influences associated with treatment, and these are 
most likely to be remembered after a diagnosis and treatment of a major 
disease.  Additional research is needed to understand the relative importance 
of factors influencing the treatment decisions and their impact on the health 
status and life span of AA men.   
 
cancer.19   Lastly, because PrCA tends to spread to bone, bone pain is a major 
source of morbidity in patients with advanced disease.  A study of older (> 60 
years) cancer survivors found pain was the most reported symptom of cancer 
treatment and being AA was associated with more cancer symptoms. Because 
of this, pain avoidance may be a higher priority for AA men.23
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